Global Acute Care Syndromic Testing Market to grow with a CAGR of 5.56% through 2028
The rising prevalence of infectious diseases
and initiatives taken by the government to support syndromic testing programs
are the major drivers for the Global Acute Care Syndromic Testing Market.
According to TechSci Research report, “Acute
Care Syndromic Testing Market –Global Industry Size, Share, Trends,
Competition, Opportunity and Forecast, 2018-2028”, Global Acute Care
Syndromic Testing Market has valued at USD 2.89 billion in 2022 and is
anticipated to project robust growth in the forecast period with a CAGR
of 5.56% through 2028. the Global Acute Care
Syndromic Testing Market is anticipated to register a high CAGR during the
forecast period. This can be ascribed to collaborations and partnerships among
leading companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market.
Dyes are used to identify the underlying cause
of a patient's symptoms, which can help to guide treatment and improve patient
outcomes. Syndromic testing can be used to diagnose a wide range of conditions.
Significant increase in infectious diseases in the healthcare industry across
the globe represents one of the key factors creating a positive outlook for the
market. Furthermore, the increasing demand for point-of-care-testing and
growing focus on preventive healthcare among individuals is also driving the
market growth.
Acute care syndromic testing is typically conducted in various
healthcare settings where patients require immediate medical attention and
rapid diagnostic results. These settings are equipped to diagnose and manage
acute medical conditions, infectious diseases, and emergencies. Such growing
global disease burden and the demand of rapid diagnosis use of Acute care
syndromic testing lead to the increasing demand for Testings.
According to a
report published in February 2022 by Oberto, Patients enrolled from March 20,
2017 to March 17, 2020. Out of 455 patients evaluated for eligibility, 278
patients were enrolled, 138 were enrolled in mPOCT (1 withdrawal) and 140 were
enrolled in the control group. Patients in mPOCT were isolated in single-occupancy
rooms for 1·8 days compared to 2·6 days in the control (exponentiated co-factor
0·70, 95% confidence interval (CI) 0·56–0·87). Therefore, the increase in the infectious
disease will drive the Acute Care Syndromic Testing Market. Hospitals,
including emergency departments and inpatient units, are primary locations for
acute care syndromic testing. They handle a wide range of acute cases and
medical emergencies where rapid and accurate diagnosis is crucial. Rapid
infrastructural development across the globe represents one of the key factors
stimulating the growth of the market.
Moreover, leading players operating in
the industry are focusing on diagnosis innovations to offer a better customer
experience. They are also engaging in partnerships and collaborations to
increase their brand presence. Apart from this, People prefer acute care
syndromic testing for several reasons, primarily due to its ability to provide
rapid, comprehensive, and accurate diagnostic information in acute medical
situations. Moreover, Acute care syndromic testing offers rapid results,
allowing healthcare providers to diagnose and initiate appropriate treatment
quickly. Timely interventions can lead to better patient outcomes and prevent
complications. This, along with the rising demand for Rapid and accurate
diagnosis is crucial in acute medical situations to initiate appropriate
treatment promptly.
Acute care syndromic testing meets this demand by providing
quick results, allowing healthcare providers to make informed decisions. There
is a growing emphasis on Point-of-Care Testing practices within the healthcare
industry, with developing and expanding point-of-care syndromic testing
solutions. These enable immediate testing and decision-making at or near the
patient's location, reducing turnaround times and improving patient outcomes.
These methods aim to provide rapid and convenient diagnostic results at or near
the patient's location. The primary goal of POCT is to enable healthcare
providers to make timely clinical decisions, initiate appropriate treatments,
and improve patient outcomes. By eliminating the need to send samples to
centralized laboratories, POCT reduces turnaround times for test results. This
speed is crucial for guiding immediate patient management.
Additionally, governments
have established frameworks and strategies for public health preparedness and
response to infectious disease outbreaks. These initiatives focus on early
detection, rapid diagnosis, and effective containment measures, often involving
the use of syndromic testing. They also develop and update epidemic and
pandemic preparedness plans that include provisions for syndromic testing.
These plans guide healthcare institutions in managing outbreaks and
emergencies. These projects serve as tangible examples of innovation and
encourage other industry players to embrace similar approaches.
Collaborations
play a significant role in advancing the Global Acute Care Syndromic Testing
Market by fostering innovation, accelerating development, improving access to
technologies, and enhancing the overall effectiveness of syndromic testing
solutions. Collaborations bring together experts from diverse fields, including
healthcare, diagnostics, technology, and research. This sharing of knowledge
and expertise leads to better understanding of complex medical challenges and
more innovative solutions. Through strategic partnerships, brands,
manufacturers, and healthcare providers can collaborate to implement
sustainable practices that effectively reduce prevalence of infectious disease,
timely diagnosis and point-of-care testing. Syndromic testing involves various
disciplines, such as microbiology, molecular biology, informatics, and clinical
medicine.
Collaborations bring together experts from these fields to create
holistic and well-rounded solutions. A state-of-the-art, fully automated
facility for surveillance of infectious diseases at Toronto’s International
Airport (Pearson) Fusion Genomics uses ONETest, the company’s on-demand
platform, to detect SARS-Cholera virus (SARS) and other respiratory agents in
wastewater.
However, competition from other diagnostics
tests and quality control and standardization are expected to slow down the
growth of the market in the coming years.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on "Global
Acute Care Syndromic Testing Market.”
The Global Acute Care Syndromic Testing Market
segmentation is based on Disease Type, Target, Sample Type, End-User, By
Company, and Region.
Some of the major companies operating in the Global
Acute Care Syndromic Testing Market include:
- Abbott
Laboratories
- Becton,
Dickinson and Company
- Biocartis NV
- bioMerieux SA
(BioFire Diagnostics)
- Danaher
Corporation (Cepheid, Inc.)
- DiaSorin S.p.A
(Luminex Corporation)
- Eurofins
Scientific (Eurofins Viracor)
- Hologic Inc.
- Laboratory
Corporation of America Holdings.
- QIAGEN N.V.
- QuantuMDx Group Ltd
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“Certain regions, particularly the North
America, are projected to exert significant demand for dyes worldwide. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhancing their Testing Technologies each
year, are expected to contribute to a remarkable growth of the Global Dyes
Market in the forecast period," said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based Global management consulting firm.
Acute Care Syndromic Testing Markets Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type
(Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases,
Tropical Diseases, Others), By Target (Bacteria, Viruses, Fungi, Parasites), By
Sample Type (Blood, Urine, Biofluids, Stool, Swabs, Others), By End User
(Hospitals, Clinical and Diagnostic Laboratories, Research and Academic
Institutions, Others), By Region, Competition has evaluated the future growth potential of
Global Acute Care Syndromic Testing Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global Acute Care Syndromic Testing Market.
Contact
TechSci
Research LLC
420 Lexington
Avenue,
Suite 300, New
York,
United States-
10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com